skip to content

Data for Roche’s Evrysdi® (risdiplam) published in New England Journal of Medicine shows significant improvement in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA)

Media

Media releases
view all

stay updated

get the latest news and updates to your inbox.